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Prospective data are limited on the course of anxiety and depression and their determinants in women
with early breast cancer. These parameters were assessed before adjuvant radiotherapy (RT) and over 5
years follow-up.
Of 2208 women recruited to the START QOL study, 35% reported clinically relevant levels of anxiety
and/or depression pre-RT; there was no signiﬁcant change in these proportions over time. However, 75%
women with high baseline anxiety recorded further high scores over time whilst one in six had high
scores at every follow-up point. Depression showed a similar pattern with lower frequencies at all time
points; very few with initial normal scores developed clinically relevant anxiety or depression over time.
Lower educational level predicted worse anxiety and depression over time; younger age predicted worse
anxiety and chemotherapy predicted worse depression. Scores in the borderline or case range for anxiety
or depression at baseline were both signiﬁcantly associated with worse mood states over 5 years.
These ﬁndings indicate the course of anxiety and depression in women with speciﬁc risk factors. This
subgroup of patients requires greater clinical attention.
 2009 Published by Elsevier Ltd.Introduction
Depression in early breast cancer has been widely reported, but
prevalence rates vary considerably,1 reﬂecting different patient
cohorts and methodological approaches, whilst anxiety disorders
have received less attention. Studies conducted in the context of
modern multimodal treatment have suggested good psychological
health on completion of treatment2 and in the longer term,3–8
which compare favourably with population samples, despite
adverse effects of treatment on other aspects of quality of life.
These outcomes suggest a level of psychological resilience,
although increased emotional distress has been observed in
younger breast cancer patients9–11 relative to older breast cancer
populations.11–13 However, long-term prospective data in large
samples of breast cancer patients across the age range are
limited14 and general measures of distress sometimes lack clinical
interpretation. Therefore, we lack an understanding of how
anxiety and depression change over the longer term and need to
determine associated predictors.15 This would indicate whichElsevier Ltd.
P, et al., The course of anxiety
.11.007patients retain vulnerability over time and develop repeated or
chronic episodes of anxiety and/or depression. This large national
clinical trial provides an opportunity to clarify these issues.
The START trials16,17 comprised two parallel multicentre rand-
omised clinical trials to determine the effects of hypofractionated
radiotherapy regimens against an international standard in women
with early breast cancer. In trial A, experimental doses of 41.6 Gy
and 39Gy, each delivered in 13 fractions over 5 weeks were
compared to the global standard of 50 Gy delivered in 25 fractions
over 5 weeks.16 In trial B, a commonly used regimen in the UK of
40 Gy delivered in 15 fractions over 3 weeks was compared with
the same standard regimen.17 Quality of life endpoints were inte-
gral to the trials18 and included assessments from 2208 participants
with a wide range of patient age and a geographic distribution.
Results of the randomised comparisons in Trials A and B have now
been published16,17 and showed no signiﬁcant differences in local
tumour control compared with the global standard but a tendency
for reduced levels of adverse effects on normal tissues was
observed for the 39 Gy and 40 Gy regimens respectively; in Trial A
results for the 41.6 Gy regimen were similar to the 50 Gy regimen.
In our analysis of the quality of life study at baseline (after
surgery, and chemotherapy where appropriate but pre-and depression over 5 years of follow-up and risk factors inwomen...,
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and/or case) compared with depression (12.0% borderline and/or
case), using the Hospital Anxiety and Depression Scale (HADS)).18
There was a higher proportion of ‘cases’ of anxiety and depression
in 735 (33.3%) patients who had received chemotherapy
(p< 0.001). In multivariate analysis, which included age and key
clinical factors (type of breast surgery, use of chemotherapy and
endocrine therapy) there was a signiﬁcant decrease in the
proportion of anxiety cases with increasing age (p< 0.001 for
trend) whilst this was not found for depression; clinical factors
were not signiﬁcantly associated. Data for the 5-year follow-up
period are now available and this report aims to add knowledge on
the course of anxiety and depression for this cohort and to assess
the stability of age and other key demographic and treatment
variables as predictors in the longer term.
Objectives
The main aim of this paper is to examine the course of anxiety
and depression over the longer term (5 years) to determine indi-
vidual patient outcomes over time.
Second, factors examined at baseline that may continue to
contribute to adjustment over time were tested to predict anxiety
and depression over a 5-year period following treatment. These are
age, education, and key treatment factors (type of surgery,
receiving adjuvant chemotherapy and endocrine therapy). Baseline
anxiety and depression categories were included in the model to
account for the effect of these co-morbidities.
We hypothesised that age and education would be predictive
of anxiety and depression over time but that clinical factors would
not.
Materials and methods
Study participants
Women aged over 18 years with early breast cancer who had
completed breast surgery (breast-conserving surgery (BCS) or
mastectomy (Mx), without reconstruction, undergone adjuvant
chemotherapy (CT), where appropriate, had commenced endocrine
therapy and had been prescribed radiotherapy, were eligible for
entry into the START trials.16,17 Participation in the trials was open
to all UK centres providing radiotherapy treatment for patients
with early breast cancer between February 1999 and October 2002.
The trials were run in parallel with centres choosing whether to
participate in Trial A or B. Centres could also choose whether or not
to participate in the QOL study and all patients in participant
centres were potentially eligible to take part; they were invited to
participate by the clinical team. The START trials were approved by
the relevant local ethics committees of all participating centres.
Data from the trials A and B have been combined, as a compar-
ison of the randomised radiotherapy schedules was not the purpose
of this paper. This provides a unique cohort of UK women receiving
treatment for early breast cancer.
Procedures
Written informed consent for the QOL study was obtained at the
patient’s planned visit by staff in the participating centres prior to
randomisation. Patients also completed a baseline QOL question-
naire booklet in the clinic before randomisation. Follow-up ques-
tionnaires were mailed from the Trials Ofﬁce at The Institute of
Cancer Research for completion at home at 6,12 24 and 60 months
after randomisation, having ﬁrst checked the patient’s current
health status with their clinical team. Telephone or mailed promptsPlease cite this article in press as: Hopwood P, et al., The course of anxiety
The Breast (2009), doi:10.1016/j.breast.2009.11.007were sent within 3 weeks if questionnaires were not returned.
Patients who relapsed were approached according to advice from
the responsible clinical team.
Measures
Demographic information
Age at randomisation was recorded for all patients and educa-
tional level was collected at 1 year (as part of a health economics
(HE) assessment). The HE assessments were mailed to patients’
homeswith the QOL booklets and returned in a prepaid envelope to
the Trials Centre. Ethnicity and civil status were not routinely
collected in the trial.
Clinical characteristics used in the analysis, available from the
clinical database included type of surgery (Mx or BCS), use of
adjuvant chemotherapy and endocrine therapy.18
Quality of Life booklets comprised the following:
Anxiety and Depression were measured using the Hospital
Anxiety and Depression Scale.19 This comprised two 7-item
subscales for symptoms of anxiety and depression respectively;
each item was rated on a 4-point scale (scored 0–3). This measure
has shown stable dimensional structure and reliability across
settings and age groups with modest effects of demographics on
scores20–22 in population samples. An advantage is the use of
threshold scores for possible (borderline) or probable clinical (case)
levels of anxiety and depression.
Body image was evaluated using the 10-item Body Image Scale
(BIS) designed for use with cancer patients23 and Quality of Lifewas
evaluated using the EORTC QOLQ-C30 general cancer quality of life
scale24 and the 23 item breast cancer module (BR23).25 The BIS and
QOL measures were not included in this analysis.
Scoring and statistical analysis
Recommended threshold scores were used to estimate levels of
anxiety and depression, scores11 on either the anxiety or
depression subscales indicated probable case disorder; those
between 8 and 10 indicated borderline disorder and those between
0 and 7 were considered normal, according to recommended
thresholds.19
Patterns of change in the course of Anxiety and Depressionwere
examined by plotting the frequencies of case, borderline and
normal subscale categories of anxiety and depression respectively
over time for subgroups of women who scored in each of these
categories at baseline. Womenwith baseline scores and at least one
additional HADS assessment were included. Frequencies were
calculated separately for women who completed all assessments.
The repeated measurements of anxiety (normal, borderline,
case) from baseline to 5 years follow-up were analysed using the
proportional odds logistic model with random intercepts. This
model analyses the cumulative probabilities of borderline and case
anxiety, appropriately taking account of the within-patient corre-
lation induced by repeated measurements. The gllamm
command26 implemented in the STATA software (STATA 9.2) was
used to ﬁt this model. An identical modelling strategy was used for
depression.
Predictors included in these models were years from random-
isation to questionnaire completion, patients’ demographic and
clinical characteristics. Baseline levels of depression were included
in the predictionmodel for anxiety and vice versa. As the regression
modelled all anxiety (or depression) data frombaseline to 5 years, it
was unnecessary to include baseline anxiety (or depression) as
a predictor in the corresponding model. Results are presented as
odds ratios (OR) with 95% conﬁdence intervals (CI) and p-values.
The interpretation of the OR for anxiety is that for a one-unitand depression over 5 years of follow-up and risk factors inwomen...,
Table 1
Demographic and clinical characteristics of 2208 patients in the START QOL study.
Patient characteristic Number of patients (%)
Age
20–29 11 (0.5)
30–39 116 (5.3)
40–49 391 (17.7)
50–59 858 (38.9)
60–69 573 (26.0)
70–79 241 (10.9)
80–89 18 (0.8)
Mean (SD) 56.9 (10.4)
Median (IQR)[ range] 56.5 (50.5–63.9)
Education (at 1 year)
School certiﬁcate or equivalent 528 (29.2%)
‘A’ level or equivalent 115 (6.4%)
Professional qualiﬁcation, degree level or above 439 (24.3%)
None of the above 725 (40.1%)
Surgery
Breast conserving surgerya 1831 (82.9)
Mastectomy 377 (17.1))
Pathological tumour size (cm)
0–0.9 182 (8.2)
1.0–1.9 1007 (45.6)
2.0–2.9 618 (28.0)
3.0 390 (17.7)
Unknown 11 (0.5)
Tumour grade
1 516 (23.4)
2 1030 (46.6)
3 612 (27.7)
Unknown 50 (2.3)
Histological type
Ductal 1722 (78.0)
Lobular 282 (12.8)
Mixed ductal and lobular 47 (2.1)
Special typesb 113 (5.1)
Not reported 44 (1.9)
Node status
Positive 692 (31.3)
Negative 1451 (65.7)
Unknown 65 ( 2.9)
Axillary surgery
Yes 2144 (97.1)
No 64 (2.9)
Adjuvant treatment
None 128 ( 5.8)
Tamoxifen only 1266 (57.3)
Chemotherapy only 224 (10.1)
Chemotherapy þ tamoxifen 537 (24.3)
Otherc 42 (1.9)
Unknown 11 (0.5)
a BCS includes patients who had undergone quadrantectomy,1 partial mastec-
tomy,4 lumpectomy1 and radiologically guided excision biopsy.8
b Special types include tubular and medullary tumours.
c Forty two received endocrine therapy with drugs other than tamoxifen.
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and case combined versus normal are OR-fold larger, and the odds
of case versus borderline and normal combined are OR-fold larger.
In other words, for a one-unit increase in the risk predictor, we
would expect an OR-fold deterioration of the anxiety status. The
same interpretation applies to the depression model.
No formal account for missing data was carried out as rates of
incomplete assessments (not due to death) were very low. The
regression models were performed on patients with available data
for all of the predictors and at least one repeated measurement for
the outcome variable in question.
Results
Participant characteristics
A total of 2208 patients were recruited to the QOL study (1129
from 13 UK centres in START Trial A and 1079 from 21 UK centres in
START Trial B); this represented 49% of the overall trial cohorts. The
median proportion per centre of trial patients entered into the QOL
study out of those eligible for QOL was 91.3% (IQR 75.0–96.9%).
Uptake rates varied between centres; reasons for non-accrual were
not routinely collected but anecdotally were found largely due to
resource limitations involved in approaching patients; the number
of patients declining was not recorded.
The cohort had a median age of 56.5 years (range 26–86 years):
518 (23.5%) were aged under 50 years at baseline assessment
(considered pre-menopausal). Most women (82.9%) underwent
breast-conserving surgery (BCS) and 94.2% received adjuvant
systemic therapy; of these 34.6 had received chemotherapy (24.4%
with and 10.2% without tamoxifen). Similar proportions of younger
and older women had BCS but a greater proportion of younger
women (66.2%) than older women (25.0%) received chemotherapy.
Educational level and clinical characteristics are shown in Table 1.
Compliance and missing data
A total of 281 (10%) patients died or withdrew during the
quality of life study period; the numbers of patients who withdrew
or died at 6 months, 1, 2 and 5 years were 21, 31, 61 and 168,
respectively. Reasons for withdrawal or refusal were not requested.
Allowing for deaths and withdrawals, completion rates for the self-
report measures were high: 2181 patients (98.8%) at baseline and
94.7%, 93.3%, 91.3% and 91.2% at 6 months, 1, 2 and 5 years,
respectively.
Educational status was available for 1807 women (82%) at year 1
when this information was ﬁrst collected; 27 patients had with-
drawn, 28 had died, 126 did not return forms, 118 did not supply
their educational status and 102 received an earlier version of the
questionnaire which did not ask for this information.
Point prevalence of anxiety and depression over time
The prevalence of borderline or case anxiety, depression or both
was 34.9% at baseline. Only 9.4% patients had co-existing anxiety
and depression at the borderline or case level at this time point.
Results for the separate anxiety and depression subscales are
shown in Fig. 1; these show that rates for anxiety were three times
higher than those for depression. Therewas no clinically signiﬁcant
change in the absolute proportions of patients exhibiting anxiety
and depression over time or in the relative increase of anxiety over
depression.
Women aged under 50 at baseline (proxy pre-menopausal) had
higher rates of borderline and case levels of anxiety compared with
women aged 50 and over (41.5% vs. 29.6) whilst depression rates
were similar between the age groups (14.9% vs. 11.0%, respectively).Please cite this article in press as: Hopwood P, et al., The course of anxiety
The Breast (2009), doi:10.1016/j.breast.2009.11.007When 10-year age groups were considered, a gradient of decreasing
levels of anxiety with increasing age was observed but there was
little variation in the frequency of depression by age (Fig. 2a and b);
the age effect was consistent over time and is shown at 5 years
(Fig. 2c and d).
The proportion of women with case anxiety varied little over
time (from 14.4% to 12.6% at 60 months) whilst the pattern for
women with case depression was similar, although numbers were
very small (3.1% at baseline and 3.3% at 60 months, respectively) as
shown in Fig. 1. A limitation of these subscale prevalence rates
over time is the lack of detail as to which women have repeated
high scores and how many improve or worsen at different timeand depression over 5 years of follow-up and risk factors inwomen...,
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Fig. 1. Observed distributions of anxiety and depression over time.
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points.
The course of anxiety and depression over time: analysis of
individual patient scores
We observed different patterns of continuation, improvement,
or resolution of anxiety and depression over timewhen frequencies
were examined for those womenwho were categorised at baseline
as having case, borderline or normal levels of anxiety or depression
on the respective subscales (Fig. 3). Considering the course of
anxiety, 313 women reported case anxiety at baseline and 306
(97.8%) had at least one follow-up assessment (range 1–4). Of these,
three quarters (228 women) rated as cases on at least one further
occasion and hence only a quarter did not have a further episode
over time. A total of 193 (61.7%) of the 313 women had all follow-up
assessments and of these one in six (18.8%) rated as cases at all four
follow-ups over 5 years whilst 74.6% rated as cases on at least one
subsequent assessment.Please cite this article in press as: Hopwood P, et al., The course of anxiety
The Breast (2009), doi:10.1016/j.breast.2009.11.007With respect to depression, 67 women reported case levels of
depression at baseline and nearly two-thirds (42/66) with at least
one follow-up (range 1–4) reported case depression on a further
occasion over 5 years. A total of 38 (57%) women completed all four
follow-ups and of these only 5 (13.2%) rated as cases on all occa-
sions whilst over two-thirds (68.4%) rated as cases on at least one
occasion. As shown in Fig. 3, there was a gradual decrease in the
proportion of women who reported a further case level of anxiety
or depression at successive time points.
In contrast, very few women with normal scores at baseline
reported an increase in anxiety or depression to borderline or case
level over time as shown in Fig. 3. Allowing for missing data, only
4.1–5.2% became anxiety cases at any successive follow-up point
and so therewas a high likelihood of remaining in the normal range
for anxiety over time given a normal score at baseline. As shown in
Fig. 3, an even lower rate was observed for depression.
Fig. 3 also shows that women with initial borderline anxiety or
depression showed a pattern of greater recovery (the proportion ofand depression over 5 years of follow-up and risk factors inwomen...,
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Fig. 2. Distribution of anxiety and depression levels by age groups at baseline and 5 years.
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level scores) over successive time points. This was examined
further by quantifying the changes over time for these borderline
groups in more detail. With respect to anxiety, 38.7% (146/377) of
womenwith at least one follow-up showed a deterioration of mood
on at least one follow-up occasion. Of 262 (67.1%) with all four
follow-ups, only 10 scored in the case range on all occasions and
just over a third (38.4%) rated at this level on at least one occasion.
Considering those with borderline depression at baseline, 27.9%
with at least one follow-up showed a deterioration to case level of
depression whilst for those with all follow-up data (112, 58%) only
one rating of case depression at every assessment was observed
and just over a quarter (26.8%) recorded a deterioration of mood on
at least one occasion. Therefore, considering reciprocal changes,
a higher proportion of women with borderline anxiety or depres-
sion at baseline showed no deterioration or an improvement in
mood over time than a worsening and this course was more
frequent for those with initial borderline depression than border-
line anxiety.Predictors of anxiety and depression
The multivariate regression analyses for anxiety and depression
respectively from baseline to 60 months were each performed on
1801 patients with data available for all the candidate predictors,
including the baseline depression category (in the anxiety model)
and baseline anxiety category (in the depression model). Educa-
tional level was the only common predictor for both anxiety and
depression (p< 0.01;test for trend) in eachmodel (Tables 2a and2b).
Anxiety status improved with follow-up time (p¼ 0.041) whilst
younger age (p< 0.001) and worse baseline depression (borderline
or case versus normal category; p< 0.001 for each) were signiﬁcant
in predicting worse anxiety over time (Table 2a). Clinical factors
had no signiﬁcant effect on the risk of anxiety over time (Table 2a).
The severity of depression (normal, borderline or case) was not
affected by follow-up time or age (Table 2b) but increased in
women who had received adjuvant chemotherapy (p¼ 0.011);
other clinical factors had no effect. Case or borderline anxiety scoresPlease cite this article in press as: Hopwood P, et al., The course of anxiety
The Breast (2009), doi:10.1016/j.breast.2009.11.007at baseline also signiﬁcantly increased the risk of worse depression
compared to those with anxiety scores in the normal range
(p< 0.001 for each) (Table 2b).Discussion
An important and novel ﬁnding of this study is that different
frequencies and patterns of change over time can be distinguished
for different levels of severity of anxiety and depression at the time
of presentation for radiotherapy treatment. Most women who
presented with a probable case level of anxiety before starting
radiotherapy treatment reported repeated high anxiety over time.
A similar course was observed for depression, albeit with many
fewer womenwith clinically relevant depression scores at baseline.
This ﬁnding was observed for women with all follow-up assess-
ments as well as thosewith one ormoremissing evaluations so that
the rate of repeat episodes did not appear to be related to the
number of ratings completed. In marked contrast, far fewer women
with a normal level of anxiety or depression at baseline experi-
enced increases in these mood states over time, reﬂecting a stable
level of well-being for these women. The course of both borderline
anxiety and borderline depressionwas intermediate between these
two very different patterns and generally showed more improve-
ment in their mood state over time than deterioration. These
ﬁndings from the analysis of individual patient scores need to be
considered in the context of the results of the change in group
proportions of anxiety and depression over time (Fig 1), inwhich no
signiﬁcant change in the rates of borderline or case anxiety and
depression were observed over 5 years of follow-up. This is an
important outcome in itself but we have shown that a different
approach is warranted to examine individual variation and identify
women at risk of increased psychological morbidity.
We cannot comment on the duration of episodes of anxiety and
depression and this is an area that warrants more research to
inform intervention studies. Burgess et al., 6 conducted a detailed
study of psychological morbidity over 5 years and reported that 40%
of women aged 60 or less had episodes lasting 90 days or more but
the authors did not discriminate between anxiety and depressionand depression over 5 years of follow-up and risk factors inwomen...,
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Fig. 3. Patterns of change over time for baseline frequencies of case, borderline and normal categories of anxiety and depression.
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ARTICLE IN PRESSor severity of distress. The detriment in well-being due to anxiety
may not be apparent in studies that have focussed on depression:
overall, 90% of anxious women in the START trial reported no
concurrent depressive symptoms, so ignoring this morbidity will
lead to underreported distress.
Our ﬁndings are comparable with other studies with other
studies using the HADS with respect to prevalence rates of anxiety
and depression,27 risk factors 27–29 and increased anxiety over
population rates.28 The vulnerability of younger women to
psychological distress was consistent with other research 4,9–11,30
but in our cohort therewas a clear linear increase in rates of anxiety
with decreasing age but no age effect on rates of depression.
Research has been less consistent in the association of mood
disorder and older women, where both good mental health 2,5 and
deterioration over time were observed 12,13 and methodological
factors may account for these differences.Please cite this article in press as: Hopwood P, et al., The course of anxiety
The Breast (2009), doi:10.1016/j.breast.2009.11.007Educationwas a predictor of both anxiety and depression in this
study which also conﬁrms other reports. However, achieving an ‘A’
level of attainment was not signiﬁcantly different from education
below the minimum school certiﬁcate level in the START trial and
this is likely to be due to relatively smaller numbers in this
subgroup; the largest subgroup (40%) was for women not achieving
the lowest level of attainment. Several studies have found no effect
for type of surgery, as in our study, and have also failed to observe
a signiﬁcant predictive effect for systemic therapy,2,3,5,6,28–31 whilst
receiving adjuvant chemotherapy increased the risk of depression
in the START cohort, in contrast to our ﬁnding at baseline. This is
unexplained but the onset of the menopause and oestrogen
decline, which result from chemotherapy, have been associated
with depression in some reports.
Patients’ initial ratings of anxiety and depression were a clini-
cally relevant risk factor for further episodes of mood disorder andand depression over 5 years of follow-up and risk factors inwomen...,
Table 2a
Results of prediction model for anxiety (normal, borderline, case).
Predictor Odds ratio (95% CI) p-value
Follow-up time (per year increase) 0.96 (0.93–0.998) 0.041
Age (per year increase) 0.94 (0.92–0.96) <0.001
Type of surgery (mastectomy vs.
conservative surgery)
0.79 (0.53–1.19) 0.265
Chemotherapy (yes vs. no) 1.24 (0.78–1.99) 0.366
Endocrine therapy (yes vs. no) 0.89 (0.61–1.30) 0.547
Time since surgery (per 10% increase) 0.98 (0.95–1.00) 0.051
Education (school certiﬁcate or
equivalent vs. no qualiﬁcation)
0.57 (0.40–0.81) 0.002
Education (A-level or equivalent vs.
no qualiﬁcation)
0.81 (0.45–1.47) 0.485
Education (professional qualiﬁcation/degree
or above vs. no qualiﬁcation)
0.39 (0.27–0.57) <0.001
Depression month 0 (borderline vs. normal) 17.72 (10.86–28.90) <0.001
Depression month 0 (case vs. normal) 81.17 (37.11–177.55) <0.001
*The trend effect was signiﬁcant (p< 0.01).
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the HADS is very well accepted by patients, it could form a role as
a screening tool in clinical practice.32–34
Our ﬁndings highlight the value of QOL sub-studies in cancer
therapy trials, in generating well-deﬁned patient samples across
a wide age and geographic range with long-term follow-up, which
are strengths of our study. A further strength was the high level of
compliance with questionnaire completion over 5 years and low
level of missing data, in comparison with many psychosocial
studies. However, a limitation of the trial setting is the lack of an
assessment prior to all cancer treatment and lack of coverage of
some demographic and psychosocial factors of relevance, such as
social support and past psychiatric history. Moreover, trial cohorts
evenwith quite broad entry criteria do not represent all patients in
clinical care. The sample was drawn from all parts of the UK but the
proportions from London and the South of England were over-
represented in comparison with the annual distribution of new
breast cancer cases for these areas35 (46.3% vs. 35%, respectively)
and any effect of this bias is unknown.
All self-report measures have limitations in their accuracy of
measuring psychological morbidity and although the HADS is very
widely used in research it could underestimate depression in
cancer patients36 and so true diagnostic rates should not be directly
extrapolated from these data. Clinical psychological assessments
can take account of individual risk and resilience and monitor the
process of adjustment and coping, which is often necessary before
providing further intervention. The assessment of psychologicalTable 2b
Results of prediction model for depression (normal, borderline, case).
Predictor Odds ratio (95% CI) p-value
Follow-up time (per year increase) 1.02 (0.97–1.07) 0.436
Age (per year increase) 1.00 (0.98–1.02) 0.874
Type of surgery (mastectomy vs.
conservative surgery)
0.94 (0.60–1.49) 0.799
Chemotherapy (yes vs. no) 2.07 (1.18–3.62) 0.011
Endocrine therapy (yes vs. no) 1.23 (0.79–1.92) 0.359
Time since surgery (per 10% increase) 0.99 (0.97–1.02) 0.737
Education (school certiﬁcate or
equivalent vs. no qualiﬁcation)
0.64 (0.43–0.96) 0.032
Education (A-level or equivalent vs.
no qualiﬁcation)
0.85 (0.44–1.67) 0.641
Education (professional qualiﬁcation/degree
or above vs. no qualiﬁcation)
0.42 (0.26–0.65) <0.001
Anxiety month 0 (borderline vs. normal) 7.82 (5.11–11.98) <0.001
Anxiety month 0 (case vs. normal) 57.27 (36.04–91.00) <0.001
*The trend effect was signiﬁcant (p< 0.01).
Please cite this article in press as: Hopwood P, et al., The course of anxiety
The Breast (2009), doi:10.1016/j.breast.2009.11.007morbidity is a priority, however, as its associations with other
detriments in quality of life are often reported.
Conclusion
Women presenting with probable case anxiety and/or depres-
sion before their radiotherapy treatment are at high risk for further
episodes whilst those with normal mood are likely to remain
psychologically well over time. Demographic rather than clinical
factors affected risk proﬁles; these ﬁndings are useful indicators of
risk and resilience for clinical teams managing women with early
breast cancer.
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